Clinical Trials

  • The main purpose of this study is to: Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer.
  • We are doing this study to find out if tisotumab vedotin treats ovarian cancer. We want to see if patients with your kind of ovarian cancer respond to the drug. We want to see how long it takes patients to respond to tisotumab vedotin and how long the response lasts. We also want to learn more about any side effects patients have when they get tisotumab vedotin.Tisotumab vedotin is a type of drug called an antibody drug conjugate or ADC. ADCs usually have 2 parts. Antibody: Antibodies are part of your immune system. Usually, they help protect you from getting sick.
  • Principal Investigator

    Catherine Monk, PhD
    Do you ever wish there was more information on how to handle the challenges of pregnancy and having a new baby? This study looks into whether certain behavioral techniques used by mothers can help their babies sleep more and cry less and, in turn, improve women's moods and child outcomes. The study starts when you are in your third trimester of pregnancy and lasts until your baby is about 4 months old.
  • Principal Investigator

    Catherine Monk, PhD
    Do you ever wish there was more information on how to handle the challenges of pregnancy and having a new baby? This study looks into whether certain behavioral techniques used by mothers can help their babies sleep more and cry less and, in turn, improve womens moods and child outcomes. The study starts when you are in your third trimester of pregnancy and lasts until your baby is about 4 months old.
  • Principal Investigator

    Carolyn L. Westhoff, MD
    The study is looking to evaluate levonogestrel butanoate as a possible new long-acting injectable for birth control. Levonogestrel butanoate is a type of hormone called progestin that has a long history of clinical use in a variety of birth control methods (e.g. pills, intrauterine devices, implants) and its efficacy and safety are well recognized. This study is seeking for healthy female volunteers between the ages of 18-40 years of age.
  • When women have a cesarean delivery, there is an amount of bleeding. Occasionally (in less than 5 of every 100 births) there is severe bleeding that can place the mothers health at risk. When there is too much bleeding after a cesarean delivery, women are given medicines, blood transfusions, or possibly need another surgery. Tranexamic acid is routinely used to lessen the chance of hemorrhage. It works by making your blood clot sooner. It is not routinely used for cesarean sections. We are doing this study to see if this drug also works for women who are having a cesarean section.
  • The purpose of this study, which involves research, is being done to see how well an investigational new drug and study device combination will work to treat people with pre-cancerous cells on the cervix caused by human papillomavirus (HPV). The treatment combination is testing a drug, called VGX-3100, given by injection and used with the study device, CELLECTRA 5PSP, that delivers a small electric charge through 5 needles to increase the amount of the study drug taken up by muscle.

Pages